Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Covidien plc

Related COV
Argus Gives Medtronic Improved Prognosis, Expects Nearly 10% Future Growth
Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression

In a report published Monday, Goldman Sachs Group reiterated its Neutral rating on Covidien plc (NYSE: COV), and slightly raised its price target from $62.00 to $63.00.

Goldman Sachs noted, “On Monday, December 31, Covidien launched a generic version of the attention deficit hyperactivity disorder drug (ADHD) Concerta. The company will offer the product in 27, 36, and 54 milligram dose strengths, and Mallinckrodt intends to file an abbreviated new drug application for the 18mg dose in 1QCY13. The company will also have the 36mg and 54mg doses available in 1QCY13. Management indicated the company has six-month exclusivity on the doses approved today. For reference, Concerta was a $1bn+ branded product marketed by J&J, and Watson is the only other generic competitor. In conjunction with the FDA approval, Covidien raised guidance for the Pharmaceutical segment (17% of sales) from 1%-4% to 3%-6%. Total company targets are unchanged.”

Covidien plc closed on Friday at $56.31.

Latest Ratings for COV

Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqual-Weight
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings


Related Articles (COV)

View Comments and Join the Discussion!

Partner Center